Floatz logo

Brivaracetam

Epilepsy

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.Small moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
73/ 100

Competitive context

64 Active assets in the Epilepsy cohort.

Asset / SponsorPhaseRating
Lacosamide
Second Affiliated Hospital of Guangzhou Medical University
Phase 4BBB
Levetiracetam
Beijing Tiantan Hospital
Phase 4BBB
Lamotrigine
Assiut University
Phase 4BBB
Topiramate
Université de Sherbrooke
Phase 4BBB
Eslicarbazepine Acetate
Bial - Portela C S.A.
Phase 4BBB

View all 50 →

Same molecule, other indications

Brivaracetam is also rated in:

focal epilepsyActive
BBB
Indicative · Phase 3
74 / 100
View asset →
spinal cord injuryActive
BB
Indicative · Phase 3
68 / 100
View asset →
Unverricht-Lundborg syndromeDormant
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →